News | Coronavirus (COVID-19) | July 24, 2020

Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19

FDA In Brief describes findings from real-world data study reveal higher risk of hospitalization and death among cancer patients with COVID-19, underscoring health disparities

FDA In Brief describes findings from real-world data study reveal higher risk of hospitalization and death among cancer patients with COVID-19, underscoring health disparities

July 24, 2020 — The following quote is attributed to Harpreet Singh, M.D., Associate Director, Cancer in Older Adults and Special Populations, FDA’s Oncology Center of Excellence; and Director, Division of Oncology 2, FDA’s Center for Drug Evaluation and Research:

  • The FDA’s Oncology Center of Excellence (OCE) and SyapseExternal Link Disclaimer presented data at the American Association of Clinical Research (AACR) COVID-19 and CancerExternal Link Disclaimer meeting on an analysis of more than 212,000 health records of people living with cancer across two major health systems in the Midwestern United States.
  • The analysis found that cancer patients who also had COVID-19 are more likely (compared to those without COVID-19) to have: (1) other health conditions (e.g., kidney failure, obesity and heart disease), (2) increased rates of hospitalization and invasive mechanical ventilation, and (3) a 16-fold increased mortality risk. The researchers also underscored evidence for health care disparities among cancer patients with COVID-19.
  • This presentation is part of OCE’s partnerships with experts in healthcare data and analytics to investigate characteristics and clinical outcomes of patients with cancer who are infected with SARS-CoV-2, the virus that causes COVID-19. This work builds upon several initiatives under way across FDA that leverage real-world data to improve understanding of COVID-19. These efforts include FDA’s participation in the COVID-19 Evidence AcceleratorExternal Link Disclaimer, organized by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research.
  • The OCE continues to engage with stakeholders and collaborate with partners on opportunities to apply data from diverse sources to inform its understanding of COVID-19 in people with cancer.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

For more information: www.fda.gov

Related Coronavirus Content:

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

Cardiac Imaging Best Practices During the COVID-19 Pandemic

RSNA Publishes COVID-19 Best Practices for Radiology Departments

ASE Guidelines for the Protection of Echocardiography Providers During the COVID-19 Outbreak
New CT Scoring Criteria for Timely Diagnosis, Treatment of Coronavirus Disease

FDA Issues New Policy for Imaging Systems During COVID-19

VIDEO: COVID-19 Precautions for Cardiac Imaging —  Interview with Stephen Bloom, M.D.

A Review of Studies Cautions Against Chest CT for Coronavirus Diagnosis

New Research Finds Chest X-ray Not Reliable Diagnostic Tool for COVID-19

VIDEO: Radiology Industry Responding to COVID-19

University of Washington Issues Radiology Policies for COVID-19

VIDEO: Best Practices for Nuclear Cardiology During the COVID-19 Pandemic — Interview with Hicham Skali, M.D.

New Research Highlights Blood Clot Dangers of COVID-19

Survey Reveals Most Medical Practices are Now Using Telehealth Due to COVID-19

CMS Offers Recommendations on Reopening Healthcare in Areas of Low COVID-19 Cases

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Radiologists Describe Coronavirus CT Imaging Features

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

ACC COVID-19 recommendations for the cardiovascular care team

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

The Cardiac Implications of Novel Coronavirus

Related Content

64-Year-Old Man With Clear Cell Likelihood Score (ccLS) 5 Renal Masses

64-Year-Old Man With Clear Cell Likelihood Score (ccLS) 5 Renal Masses. Coronal T2-weighted single shot fast spin echo and coronal T1-weighted fat-saturated spoiled gradient echo acquired during corticomedullary phase—ccLS5 lesion outlined red for clarity.

News | Magnetic Resonance Imaging (MRI) | July 22, 2021
This change will be debuted at HIMSS 2021, and Vital will be exhibiting as Canon Medical for the first time
News | Information Technology | July 22, 2021
July 22, 2021 — Canon Medical Systems Corpora
SurveyVitals, a leading patient experience analytics provider, announced it has joined forces with the Radiology Business Management Association (RBMA) to launch Postmarks, a real-time patient and partner feedback software solution
News | Patient Engagement | July 22, 2021
July 22, 2021 — SurveyVitals, a leading patient experie
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...